Progression and biomarkers for Parkinson's disease: Merging motor with nonmotor symptoms

Kallol Ray Chaudhuri

doi:10.1212/WNL.0000000000002664

Progression and biomarkers for Parkinson's disease: Merging motor with nonmotor symptoms

Kallol Ray Chaudhuri

Basic and Clinical Neuroscience

Research output: Contribution to journal › Editorial › peer-review

4 Citations (Scopus)

Abstract

The conceptualization of clinical aspects of Parkinson disease (PD) and its pathophysiology has changed considerably since Braak's description of a “bottom-up” progression of Lewy body pathology from the lower medulla and the olfactory bundle.1 Substantia nigra involvement, once the hallmark of PD pathology, is now recognized to occur at a substantially later stage, with nonmotor symptoms (NMS) occurring before classical motor signs are evident. Recent diagnostic criteria have been devised to predict prodromal PD2 in which PD NMS underpin the prodromal stage. The phenotypic heterogeneity of PD reflects the convergence of deficits in multiple transmitter systems and non-dopamine pathways, including the cholinergic, noradrenergic, and serotonergic systems.3–5 This formulation has now been translated to clinical practice with the recent description of several nonmotor subtypes of PD.6

Original language	English
Pages (from-to)	128-129
Number of pages	2
Journal	Neurology
Volume	87
Issue number	2
Early online date	6 May 2016
DOIs	https://doi.org/10.1212/WNL.0000000000002664
Publication status	Published - 12 Jul 2016

Keywords

Biomarkers, Parkinsons disease, Non motor

Access to Document

10.1212/WNL.0000000000002664

Cite this

@article{0b2a64c526a848b9909d0a42ef4d4021,

title = "Progression and biomarkers for Parkinson's disease: Merging motor with nonmotor symptoms",

abstract = "The conceptualization of clinical aspects of Parkinson disease (PD) and its pathophysiology has changed considerably since Braak's description of a “bottom-up” progression of Lewy body pathology from the lower medulla and the olfactory bundle.1 Substantia nigra involvement, once the hallmark of PD pathology, is now recognized to occur at a substantially later stage, with nonmotor symptoms (NMS) occurring before classical motor signs are evident. Recent diagnostic criteria have been devised to predict prodromal PD2 in which PD NMS underpin the prodromal stage. The phenotypic heterogeneity of PD reflects the convergence of deficits in multiple transmitter systems and non-dopamine pathways, including the cholinergic, noradrenergic, and serotonergic systems.3–5 This formulation has now been translated to clinical practice with the recent description of several nonmotor subtypes of PD.6",

keywords = "Biomarkers, Parkinsons disease, Non motor ",

author = "{Ray Chaudhuri}, Kallol",

year = "2016",

month = jul,

day = "12",

doi = "10.1212/WNL.0000000000002664",

language = "English",

volume = "87",

pages = "128--129",

journal = "Neurology",

issn = "0028-3878",

publisher = "LIPPINCOTT WILLIAMS & WILKINS",

number = "2",

}

TY - JOUR

T1 - Progression and biomarkers for Parkinson's disease

T2 - Merging motor with nonmotor symptoms

AU - Ray Chaudhuri, Kallol

PY - 2016/7/12

Y1 - 2016/7/12

N2 - The conceptualization of clinical aspects of Parkinson disease (PD) and its pathophysiology has changed considerably since Braak's description of a “bottom-up” progression of Lewy body pathology from the lower medulla and the olfactory bundle.1 Substantia nigra involvement, once the hallmark of PD pathology, is now recognized to occur at a substantially later stage, with nonmotor symptoms (NMS) occurring before classical motor signs are evident. Recent diagnostic criteria have been devised to predict prodromal PD2 in which PD NMS underpin the prodromal stage. The phenotypic heterogeneity of PD reflects the convergence of deficits in multiple transmitter systems and non-dopamine pathways, including the cholinergic, noradrenergic, and serotonergic systems.3–5 This formulation has now been translated to clinical practice with the recent description of several nonmotor subtypes of PD.6

AB - The conceptualization of clinical aspects of Parkinson disease (PD) and its pathophysiology has changed considerably since Braak's description of a “bottom-up” progression of Lewy body pathology from the lower medulla and the olfactory bundle.1 Substantia nigra involvement, once the hallmark of PD pathology, is now recognized to occur at a substantially later stage, with nonmotor symptoms (NMS) occurring before classical motor signs are evident. Recent diagnostic criteria have been devised to predict prodromal PD2 in which PD NMS underpin the prodromal stage. The phenotypic heterogeneity of PD reflects the convergence of deficits in multiple transmitter systems and non-dopamine pathways, including the cholinergic, noradrenergic, and serotonergic systems.3–5 This formulation has now been translated to clinical practice with the recent description of several nonmotor subtypes of PD.6

KW - Biomarkers, Parkinsons disease, Non motor

UR - http://www.scopus.com/inward/record.url?scp=84978959084&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000002664

DO - 10.1212/WNL.0000000000002664

M3 - Editorial

SN - 0028-3878

VL - 87

SP - 128

EP - 129

JO - Neurology

JF - Neurology

IS - 2

ER -

Progression and biomarkers for Parkinson's disease: Merging motor with nonmotor symptoms

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this